Looks like Heather Bresch; Mylan, and er everybody at Mylan for that matter may be in trouble. According to Senate officials in Washington, a formal probe into Bresch’s decision to hike the price of EpiPen — one of America’s most prominent life saving pharma products.
Officials announced in a statement that a probe had been launched after days of controversy, and, suggestions that Bresch may have tried to pull a Martin Shrkeli and hike the price regardless of public outrage. Amid the outrage, Bresch, had announced that assistance for those in dire need of the EpiPen had been increased, but, refused to lower the price in any form itself.
“Our review of this matter will be robust, thorough, and bipartisan,” they said. “Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases.”
Be First to Comment